Literature DB >> 11172040

Integrin activation controls metastasis in human breast cancer.

B Felding-Habermann1, T E O'Toole, J W Smith, E Fransvea, Z M Ruggeri, M H Ginsberg, P E Hughes, N Pampori, S J Shattil, A Saven, B M Mueller.   

Abstract

Metastasis is the primary cause of death in human breast cancer. Metastasis to bone, lungs, liver, and brain involves dissemination of breast cancer cells via the bloodstream and requires adhesion within the vasculature. Blood cell adhesion within the vasculature depends on integrins, a family of transmembrane adhesion receptors, and is regulated by integrin activation. Here we show that integrin alpha v beta 3 supports breast cancer cell attachment under blood flow conditions in an activation-dependent manner. Integrin alpha v beta 3 was found in two distinct functional states in human breast cancer cells. The activated, but not the nonactivated, state supported tumor cell arrest during blood flow through interaction with platelets. Importantly, activated alpha v beta 3 was expressed by freshly isolated metastatic human breast cancer cells and variants of the MDA-MB 435 human breast cancer cell line, derived from mammary fat pad tumors or distant metastases in severe combined immunodeficient mice. Expression of constitutively activated mutant alpha v beta 3(D723R), but not alpha v beta 3(WT), in MDA-MB 435 cells strongly promoted metastasis in the mouse model. Thus breast cancer cells can exhibit a platelet-interactive and metastatic phenotype that is controlled by the activation of integrin alpha v beta 3. Consequently, alterations within tumors that lead to the aberrant control of integrin activation are expected to adversely affect the course of human breast cancer.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11172040      PMCID: PMC29346          DOI: 10.1073/pnas.98.4.1853

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  31 in total

1.  In vitro bone marrow purging of multidrug-resistant cells with a mouse monoclonal antibody directed against Mr 170,000 glycoprotein and a saporin-conjugated anti-mouse antibody.

Authors:  A Dinota; P L Tazzari; M Michieli; G Visani; M Gobbi; A Bontadini; C Tassi; R Fanin; D Damiani; M Grandi
Journal:  Cancer Res       Date:  1990-07-15       Impact factor: 12.701

2.  Isolation and characterization of a platelet membrane protein related to the vitronectin receptor.

Authors:  S C Lam; E F Plow; S E D'Souza; D A Cheresh; A L Frelinger; M H Ginsberg
Journal:  J Biol Chem       Date:  1989-03-05       Impact factor: 5.157

3.  Biosynthetic and functional properties of an Arg-Gly-Asp-directed receptor involved in human melanoma cell attachment to vitronectin, fibrinogen, and von Willebrand factor.

Authors:  D A Cheresh; R C Spiro
Journal:  J Biol Chem       Date:  1987-12-25       Impact factor: 5.157

4.  Integrin distribution in malignant melanoma: association of the beta 3 subunit with tumor progression.

Authors:  S M Albelda; S A Mette; D E Elder; R Stewart; L Damjanovich; M Herlyn; C A Buck
Journal:  Cancer Res       Date:  1990-10-15       Impact factor: 12.701

5.  Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice.

Authors:  J E Price; A Polyzos; R D Zhang; L M Daniels
Journal:  Cancer Res       Date:  1990-02-01       Impact factor: 12.701

6.  Integrins and their accessory adhesion molecules in mammary carcinomas: loss of polarization in poorly differentiated tumors.

Authors:  M Pignatelli; M R Cardillo; A Hanby; G W Stamp
Journal:  Hum Pathol       Date:  1992-10       Impact factor: 3.466

7.  Distinct biological consequences of integrin alpha v beta 3-mediated melanoma cell adhesion to fibrinogen and its plasmic fragments.

Authors:  B Felding-Habermann; Z M Ruggeri; D A Cheresh
Journal:  J Biol Chem       Date:  1992-03-15       Impact factor: 5.157

8.  Involvement of integrin alpha V gene expression in human melanoma tumorigenicity.

Authors:  B Felding-Habermann; B M Mueller; C A Romerdahl; D A Cheresh
Journal:  J Clin Invest       Date:  1992-06       Impact factor: 14.808

9.  Platelet glycoproteins Ia, Ic, and IIa are physicochemically indistinguishable from the very late activation antigens adhesion-related proteins of lymphocytes and other cell types.

Authors:  K D Pischel; H G Bluestein; V L Woods
Journal:  J Clin Invest       Date:  1988-02       Impact factor: 14.808

10.  Clonal dominance detected in metastases but not primary tumors of retrovirally marked human breast carcinoma injected into nude mice.

Authors:  K Cornetta; A Moore; M Johannessohn; G W Sledge
Journal:  Clin Exp Metastasis       Date:  1994-01       Impact factor: 5.150

View more
  204 in total

Review 1.  Integrins in mammary gland development and differentiation of mammary epithelium.

Authors:  Ilaria Taddei; Marisa M Faraldo; Jérôme Teulière; Marie-Ange Deugnier; Jean Paul Thiery; Marina A Glukhova
Journal:  J Mammary Gland Biol Neoplasia       Date:  2003-10       Impact factor: 2.673

2.  Unique disulfide bonds in epidermal growth factor (EGF) domains of β3 affect structure and function of αIIbβ3 and αvβ3 integrins in different manner.

Authors:  Ronit Mor-Cohen; Nurit Rosenberg; Yulia Einav; Ehud Zelzion; Meytal Landau; Wissam Mansour; Yulia Averbukh; Uri Seligsohn
Journal:  J Biol Chem       Date:  2012-02-03       Impact factor: 5.157

3.  Plasma fibronectin promotes lung metastasis by contributions to fibrin clots and tumor cell invasion.

Authors:  Gunjan Malik; Lynn M Knowles; Rajiv Dhir; Shuping Xu; Shuting Yang; Erkki Ruoslahti; Jan Pilch
Journal:  Cancer Res       Date:  2010-05-25       Impact factor: 12.701

4.  Shear stress induced release of von Willebrand factor and thrombospondin-1 in HUVEC extracellular matrix enhances breast tumour cell adhesion.

Authors:  Noëlia Gomes; Chantal Legrand; Françoise Fauvel-Lafève
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

5.  Imaging chemically modified adenovirus for targeting tumors expressing integrin alphavbeta3 in living mice with mutant herpes simplex virus type 1 thymidine kinase PET reporter gene.

Authors:  Zhengming Xiong; Zhen Cheng; Xianzhong Zhang; Manish Patel; Joseph C Wu; Sanjiv S Gambhir; Xiaoyuan Chen
Journal:  J Nucl Med       Date:  2006-01       Impact factor: 10.057

6.  Integrin beta3 Leu33Pro polymorphism increases BRCA1-associated ovarian cancer risk.

Authors:  Anna Jakubowska; Jacek Gronwald; Janusz Menkiszak; Bohdan Górski; Tomasz Huzarski; Tomasz Byrski; Lutz Edler; Jan Lubinski; Rodney J Scott; Ute Hamann
Journal:  J Med Genet       Date:  2007-01-12       Impact factor: 6.318

7.  Impact of surgery and chemotherapy on von Willebrand factor and vascular endothelial growth factor levels in colorectal cancer.

Authors:  Ignasio Gil-Bazo; Ignacio Gil Bazo; Victoria Catalán Goni; Victoria Catalán González; Alvaro Alonso Gutiérrez; Javier Rodríguez Rodríguez; José Antonio Páramo Fernández; Juan de la Cámara Gómez; José Luis Hernández Lizoain; Jesús García-Foncillas López
Journal:  Clin Transl Oncol       Date:  2005-05       Impact factor: 3.405

8.  The structure of Rap1 in complex with RIAM reveals specificity determinants and recruitment mechanism.

Authors:  Hao Zhang; Yu-Chung Chang; Mark L Brennan; Jinhua Wu
Journal:  J Mol Cell Biol       Date:  2013-11-28       Impact factor: 6.216

9.  Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors.

Authors:  Catherine Delbaldo; Eric Raymond; Karina Vera; Luz Hammershaimb; Karen Kaucic; Stéphanie Lozahic; Michel Marty; Sandrine Faivre
Journal:  Invest New Drugs       Date:  2007-09-18       Impact factor: 3.850

10.  Hydroxyapatite mineral enhances malignant potential in a tissue-engineered model of ductal carcinoma in situ (DCIS).

Authors:  Frank He; Nora L Springer; Matthew A Whitman; Siddharth P Pathi; Yeonkyung Lee; Sunish Mohanan; Stephen Marcott; Aaron E Chiou; Bryant S Blank; Neil Iyengar; Patrick G Morris; Maxine Jochelson; Clifford A Hudis; Pragya Shah; Jennie A M R Kunitake; Lara A Estroff; Jan Lammerding; Claudia Fischbach
Journal:  Biomaterials       Date:  2019-09-11       Impact factor: 12.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.